Turpeenniemi-Hujanen T - Search Results

1

Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.

Kaprio E, Prusila R, Tokola S, Kuusisto MEL, Jantunen E, Kuitunen H, Turpeenniemi-Hujanen T, Kuittinen O. Kaprio E, et al. Among authors: turpeenniemi hujanen t. Cancer Med. 2024 Jan;13(1):e6898. doi: 10.1002/cam4.6898. Epub 2024 Jan 1. Cancer Med. 2024. PMID: 38164067 Free PMC article.

2

Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML.

Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T. Kuittinen O, et al. Anticancer Res. 1999 Sep-Oct;19(5C):4395-400. Anticancer Res. 1999. PMID: 10650782

3

MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL).

Kuittinen O, Savolainen ER, Koistinen P, Möttönen M, Turpeenniemi-Hujanen T. Kuittinen O, et al. Leuk Res. 2001 Feb;25(2):125-31. doi: 10.1016/s0145-2126(00)00104-1. Leuk Res. 2001. PMID: 11166827

4

Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.

Kuittinen O, Ruokolainen H, Turpeenniemi-Hujanen T. Kuittinen O, et al. Leuk Lymphoma. 2001 Jul;42(3):507-10. doi: 10.3109/10428190109064608. Leuk Lymphoma. 2001. PMID: 11699416

5

Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.

Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Kuittinen O, et al. Eur J Haematol. 2002 Oct;69(4):205-12. doi: 10.1034/j.1600-0609.2002.02751.x. Eur J Haematol. 2002. PMID: 12431239

6

Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.

Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T. Kuittinen O, et al. Eur J Haematol. 2003 Aug;71(2):91-9. doi: 10.1034/j.1600-0609.2003.00101.x. Eur J Haematol. 2003. PMID: 12890147

7

Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma.

Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Pennanen H, et al. Eur J Haematol. 2004 Jan;72(1):1-9. doi: 10.1046/j.0902-4441.2004.00168.x. Eur J Haematol. 2004. PMID: 14962256

8

Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey.

Kuittinen T, Wiklund T, Remes K, Elonen E, Lehtinen T, Kuittinen O, Leppä S, Putkonen M, Räty R, Turpeenniemi-Hujanen T, Nousiainen T, Jantunen E. Kuittinen T, et al. Eur J Haematol. 2005 Sep;75(3):199-205. doi: 10.1111/j.1600-0609.2005.00481.x. Eur J Haematol. 2005. PMID: 16104875

9

Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.

Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T. Pennanen H, et al. Eur J Haematol. 2008 Jan;80(1):46-54. doi: 10.1111/j.1600-0609.2007.00975.x. Epub 2007 Nov 19. Eur J Haematol. 2008. PMID: 18028436

10

Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.

Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Pennanen H, et al. Eur J Haematol. 2008 Oct;81(4):289-97. doi: 10.1111/j.1600-0609.2008.01113.x. Epub 2008 Jul 8. Eur J Haematol. 2008. PMID: 18616513

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters